261 related articles for article (PubMed ID: 22490804)
1. Zebrafish screen identifies novel compound with selective toxicity against leukemia.
Ridges S; Heaton WL; Joshi D; Choi H; Eiring A; Batchelor L; Choudhry P; Manos EJ; Sofla H; Sanati A; Welborn S; Agarwal A; Spangrude GJ; Miles RR; Cox JE; Frazer JK; Deininger M; Balan K; Sigman M; Müschen M; Perova T; Johnson R; Montpellier B; Guidos CJ; Jones DA; Trede NS
Blood; 2012 Jun; 119(24):5621-31. PubMed ID: 22490804
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels.
Bressanin D; Evangelisti C; Ricci F; Tabellini G; Chiarini F; Tazzari PL; Melchionda F; Buontempo F; Pagliaro P; Pession A; McCubrey JA; Martelli AM
Oncotarget; 2012 Aug; 3(8):811-23. PubMed ID: 22885370
[TBL] [Abstract][Full Text] [Related]
3. Healthy CD4+ T lymphocytes are not affected by targeted therapies against the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia.
Alameen AA; Simioni C; Martelli AM; Zauli G; Ultimo S; McCubrey JA; Gonelli A; Marisi G; Ulivi P; Capitani S; Neri LM
Oncotarget; 2016 Aug; 7(34):55690-55703. PubMed ID: 27494886
[TBL] [Abstract][Full Text] [Related]
4. Targeting signaling pathways in T-cell acute lymphoblastic leukemia initiating cells.
Martelli AM; Lonetti A; Buontempo F; Ricci F; Tazzari PL; Evangelisti C; Bressanin D; Cappellini A; Orsini E; Chiarini F
Adv Biol Regul; 2014 Sep; 56():6-21. PubMed ID: 24819383
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
Ksionda O; Mues M; Wandler AM; Donker L; Tenhagen M; Jun J; Ducker GS; Matlawska-Wasowska K; Shannon K; Shokat KM; Roose JP
PLoS One; 2018; 13(5):e0193849. PubMed ID: 29799846
[TBL] [Abstract][Full Text] [Related]
6. Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia.
Cani A; Simioni C; Martelli AM; Zauli G; Tabellini G; Ultimo S; McCubrey JA; Capitani S; Neri LM
Oncotarget; 2015 Mar; 6(9):6597-610. PubMed ID: 25788264
[TBL] [Abstract][Full Text] [Related]
7. A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia.
Lang F; Wunderle L; Badura S; Schleyer E; Brüggemann M; Serve H; Schnittger S; Gökbuget N; Pfeifer H; Wagner S; Ashelford K; Bug G; Ottmann OG
BMC Pharmacol Toxicol; 2020 Sep; 21(1):70. PubMed ID: 32993794
[TBL] [Abstract][Full Text] [Related]
8. Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235.
Hall CP; Reynolds CP; Kang MH
Clin Cancer Res; 2016 Feb; 22(3):621-32. PubMed ID: 26080839
[TBL] [Abstract][Full Text] [Related]
9. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia.
Reynolds C; Roderick JE; LaBelle JL; Bird G; Mathieu R; Bodaar K; Colon D; Pyati U; Stevenson KE; Qi J; Harris M; Silverman LB; Sallan SE; Bradner JE; Neuberg DS; Look AT; Walensky LD; Kelliher MA; Gutierrez A
Leukemia; 2014 Sep; 28(9):1819-27. PubMed ID: 24552990
[TBL] [Abstract][Full Text] [Related]
10. Marsdenia tenacissimae extraction (MTE) inhibits the proliferation and induces the apoptosis of human acute T cell leukemia cells through inactivating PI3K/AKT/mTOR signaling pathway via PTEN enhancement.
Wang Y; Chen B; Wang Z; Zhang W; Hao K; Chen Y; Li K; Wang T; Xie Y; Huang Z; Tong X
Oncotarget; 2016 Dec; 7(50):82851-82863. PubMed ID: 27756877
[TBL] [Abstract][Full Text] [Related]
11. Fish pharming: zebrafish antileukemia screening.
Clements WK; Traver D
Blood; 2012 Jun; 119(24):5614-5. PubMed ID: 22700692
[No Abstract] [Full Text] [Related]
12. Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen.
Cusick MF; Libbey JE; Trede NS; Eckels DD; Fujinami RS
J Neuroimmunol; 2012 Mar; 244(1-2):35-44. PubMed ID: 22245285
[TBL] [Abstract][Full Text] [Related]
13. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
[TBL] [Abstract][Full Text] [Related]
14. A small-molecule inhibitor of D-cyclin transactivation displays preclinical efficacy in myeloma and leukemia via phosphoinositide 3-kinase pathway.
Mao X; Cao B; Wood TE; Hurren R; Tong J; Wang X; Wang W; Li J; Jin Y; Sun W; Spagnuolo PA; MacLean N; Moran MF; Datti A; Wrana J; Batey RA; Schimmer AD
Blood; 2011 Feb; 117(6):1986-97. PubMed ID: 21135258
[TBL] [Abstract][Full Text] [Related]
15. An oral quinoline derivative, MPT0B392, causes leukemic cells mitotic arrest and overcomes drug resistant cancer cells.
Chao MW; Huang HL; HuangFu WC; Hsu KC; Liu YM; Wu YW; Lin CF; Chen YL; Lai MJ; Lee HY; Liou JP; Teng CM; Yang CR
Oncotarget; 2017 Apr; 8(17):27772-27785. PubMed ID: 28186963
[TBL] [Abstract][Full Text] [Related]
16. Focused chemical genomics using zebrafish xenotransplantation as a pre-clinical therapeutic platform for T-cell acute lymphoblastic leukemia.
Bentley VL; Veinotte CJ; Corkery DP; Pinder JB; LeBlanc MA; Bedard K; Weng AP; Berman JN; Dellaire G
Haematologica; 2015 Jan; 100(1):70-6. PubMed ID: 25281505
[TBL] [Abstract][Full Text] [Related]
17. The dual specificity PI3K/mTOR inhibitor PKI-587 displays efficacy against T-cell acute lymphoblastic leukemia (T-ALL).
Gazi M; Moharram SA; Marhäll A; Kazi JU
Cancer Lett; 2017 Apr; 392():9-16. PubMed ID: 28159681
[TBL] [Abstract][Full Text] [Related]
18. SB365 inhibits angiogenesis and induces apoptosis of hepatocellular carcinoma through modulation of PI3K/Akt/mTOR signaling pathway.
Hong SW; Jung KH; Lee HS; Choi MJ; Son MK; Zheng HM; Hong SS
Cancer Sci; 2012 Nov; 103(11):1929-37. PubMed ID: 22909393
[TBL] [Abstract][Full Text] [Related]
19. Calcineurin complex isolated from T-cell acute lymphoblastic leukemia (T-ALL) cells identifies new signaling pathways including mTOR/AKT/S6K whose inhibition synergize with calcineurin inhibition to promote T-ALL cell death.
Tosello V; Saccomani V; Yu J; Bordin F; Amadori A; Piovan E
Oncotarget; 2016 Jul; 7(29):45715-45729. PubMed ID: 27304189
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]